The Asia Pacificbreast cancer screening market was valued at US$ 798.57 million in 2019 and is projected to reach US$ 1,120.77 million by 2027; it is expected to grow at a CAGR of 5.4% from 2020 to 2027.
As per the Centers for Disease Control and Prevention (CDC) definition, breast cancer screening refers tochecking a woman’s breasts for cancer before there are signs or symptoms of the disease. The purpose of screening tests is to discover cancer at an early stage when it can be operated or cured. At times, a screening test detects cancer when it is very small or growingslowly.
Market Insights
Increasing Investmentsfor Research in Breast Cancer Management
Increasing research activities is likely to enhance the breast cancer screening market in Asia Pacific. For instance, “Novel combination of serum microRNA for detecting breast cancer in the early stage” was conducted in Japan. Furthermore, the government in Japan has initiated cancer control programs as it is one of the leading cause of death in Japan. Cancer screening programs are carried out throughout the country by the municipalities with the government support.
Additionally, increasing research for early diagnosis of breast cancer is likely to favor the breast cancer screening market in Australia. For instance, in October 2019, a NBCF funded (national breast cancer foundation) researcher Sydney University published theresults of pilot trial of 3D mammography (known as tomosynthesis), as per thestudy, breast cancer detection rates are higher with 3D mammography as compared withthe standard 2D mammography.
Test Type-Based Market Insights
Based on test type,the breast cancer screeningmarket is segmented into imaging test, Immunohistochemistry test, genetic test, and blood marker tests. In 2019,the imaging testsegment held the largest share of the market in 2019; moreoverit is anticipated to register the highest CAGR in the market during the forecast period.
End User-Based MarketInsights
Based onend user, the breast cancer screeningmarketis further segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019; moreoverit is estimated to register the highest CAGR in the market during the forecast period.
Strategic Insights
Product launches and approvalsarethe commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the breast cancer screeningmarketadopt the expansion, collaboration, and product launch strategies to enlarge customer base acrossthe world.These strategies allow the players to maintain their brand name globally. For instance, in October 2018, GE Healthcare launched a product, namely, the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the US. The device is FDA-approved ultrasound supplemental breast screening technology, specifically designed for detecting cancer in dense breast tissue.
By Test Type
By End User
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 798.57 Million |
| Market Size by 2027 | US$ 1,120.77 Million |
| CAGR (2020 - 2027) | 5.4% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Test Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Breast Cancer Screening Market is valued at US$ 798.57 Million in 2019, it is projected to reach US$ 1,120.77 Million by 2027.
As per our report Asia Pacific Breast Cancer Screening Market, the market size is valued at US$ 798.57 Million in 2019, projecting it to reach US$ 1,120.77 Million by 2027. This translates to a CAGR of approximately 5.4% during the forecast period.
The Asia Pacific Breast Cancer Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Breast Cancer Screening Market report:
The Asia Pacific Breast Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Breast Cancer Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Breast Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Breast Cancer Screening Market
